Overview: Anti-ds-DNA Antibody TestIntroduction: The Anti-ds-DNA Antibody Test detects antibodies linked to lupus, an autoimmune disease causing joint pain, rashes, or kidney problems. Following 2023 ACR guidelines, it uses an immunoassay for high specificity, aiding in autoimmune screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected systemic lupus erythematosus (SLE).
Other Names: Anti-ds-DNA Assay, Lupus Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Lupus antibody testing began in the 1950s with ANA tests. Anti-ds-DNA assays emerged in the 1970s, and by the 2000s, high-sensitivity immunoassays improved specificity for SLE.
Purpose: Diagnoses lupus, guides treatment, and monitors disease activity in patients with joint pain, rashes, or kidney problems.
Test Parameters: 1. Anti ds DNA Antibody
Pretest Condition: No fasting required. Collect serum or saliva at any time. Report symptoms like joint pain or rashes, and list medications like immunosuppressants.
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document lupus symptoms, autoimmune disease history, or family history of autoimmune disorders. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for immunosuppressive therapy.
Procedural Considerations: Uses an immunoassay to measure anti-ds-DNA antibodies. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Immunosuppressants may suppress antibody levels, causing false negatives. Hemolysis or improper storage can degrade samples.
Clinical Significance: Positive results confirm lupus, prompting immunosuppressive therapy. Negative results may require ANA or complement testing for confirmation.
Specialist Consultation: Consult a rheumatologist for result interpretation. A nephrologist referral is advised for kidney involvement.
Additional Supporting Tests: ANA test, complement levels, or renal function tests to confirm lupus or assess organ damage.
Test Limitations: False negatives may occur with immunosuppressive therapy. Low-level antibodies may not indicate active disease, requiring clinical correlation.
References: ACR Lupus Guidelines, 2023; Arthritis and Rheumatology, Tsokos GC, 2022.
